Metropolitan Life Insurance CO Nektar Therapeutics Transaction History

Metropolitan Life Insurance CO

  • $253 Million
  • Q2 2024

Shares

56 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$0.64 - $3.15 $854 - $4,205
-1,335 Reduced 11.77%
10,005 $7,000
Q4 2022

Jun 14, 2023
BUY
$2.03 - $4.28 $2,710 - $5,713
1,335 Added 13.34%
11,340 $25.6 Million
Q4 2022

Mar 30, 2023
BUY
$2.03 - $4.28 $7,003 - $14,766
3,450 Added 43.73%
11,340 $25,000
Q4 2022

Feb 15, 2023
BUY
$2.03 - $4.28 $7,003 - $14,766
3,450 Added 43.73%
11,340 $25,000
Q3 2022

Jun 14, 2023
SELL
$3.04 - $5.14 $6,429 - $10,871
-2,115 Reduced 21.14%
7,890 $25.2 Million
Q3 2022

Mar 30, 2023
SELL
$3.04 - $5.14 $9,548 - $16,144
-3,141 Reduced 28.47%
7,890 $25,000
Q3 2022

Nov 14, 2022
SELL
$3.04 - $5.14 $9,548 - $16,144
-3,141 Reduced 28.47%
7,890 $25,000
Q2 2022

Jun 20, 2023
BUY
$3.17 - $6.17 $3,252 - $6,330
1,026 Added 10.25%
11,031 $41,000
Q2 2022

Mar 30, 2023
BUY
$3.17 - $6.17 $23,613 - $45,960
7,449 Added 207.96%
11,031 $41,000
Q2 2022

Aug 11, 2022
BUY
$3.17 - $6.17 $34,968 - $68,061
11,031 New
11,031 $42,000
Q1 2022

May 12, 2022
SELL
$4.16 - $13.72 $14,901 - $49,145
-3,582 Closed
0 $0
Q4 2021

Jun 21, 2023
SELL
$10.83 - $18.41 $69,561 - $118,247
-6,423 Reduced 64.2%
3,582 $48,000
Q4 2021

Mar 30, 2023
SELL
$10.83 - $18.41 $285,056 - $484,569
-26,321 Reduced 88.02%
3,582 $48,000
Q4 2021

Feb 15, 2022
SELL
$10.83 - $18.41 $285,056 - $484,569
-26,321 Reduced 88.02%
3,582 $48,000
Q3 2021

Jun 21, 2023
BUY
$13.07 - $18.84 $306,190 - $441,364
23,427 Added 234.15%
33,432 $600,000
Q3 2021

Mar 30, 2023
SELL
$13.07 - $18.84 $58,096 - $83,743
-4,445 Reduced 12.94%
29,903 $537,000
Q3 2021

Nov 15, 2021
SELL
$13.07 - $18.84 $58,096 - $83,743
-4,445 Reduced 12.94%
29,903 $537,000
Q2 2021

Jun 21, 2023
BUY
$16.52 - $20.4 $402,146 - $496,597
24,343 Added 243.31%
34,348 $589,000
Q2 2021

Mar 30, 2023
BUY
$16.52 - $20.4 $59,224 - $73,134
3,585 Added 11.65%
34,348 $589,000
Q2 2021

Aug 16, 2021
BUY
$16.52 - $20.4 $566,916 - $700,066
34,317 Added 110700.0%
34,348 $589,000
Q1 2021

Jun 26, 2023
BUY
$16.56 - $25.46 $401,861 - $617,837
24,267 Added 242.55%
34,272 $685 Million
Q1 2021

Mar 30, 2023
SELL
$16.56 - $25.46 $21,312 - $32,767
-1,287 Reduced 4.02%
30,763 $615,000
Q1 2021

May 14, 2021
SELL
$16.56 - $25.46 $530,234 - $815,203
-32,019 Reduced 99.9%
31 $615,000
Q4 2020

Jun 22, 2023
BUY
$15.77 - $19.03 $347,649 - $419,516
22,045 Added 220.34%
32,050 $544,000
Q4 2020

Mar 30, 2023
SELL
$15.77 - $19.03 $12,221 - $14,748
-775 Reduced 2.36%
32,050 $544,000
Q4 2020

Feb 16, 2021
SELL
$15.77 - $19.03 $12,221 - $14,748
-775 Reduced 2.36%
32,050 $545,000
Q3 2020

Jun 26, 2023
BUY
$16.59 - $24.79 $378,583 - $565,707
22,820 Added 228.09%
32,825 $544,000
Q3 2020

Mar 30, 2023
SELL
$16.59 - $24.79 $26,311 - $39,316
-1,586 Reduced 4.61%
32,825 $544,000
Q3 2020

Nov 13, 2020
SELL
$16.59 - $24.79 $26,311 - $39,316
-1,586 Reduced 4.61%
32,825 $545,000
Q2 2020

Jun 26, 2023
BUY
$16.86 - $23.44 $411,485 - $572,076
24,406 Added 243.94%
34,411 $796,000
Q2 2020

Mar 30, 2023
SELL
$16.86 - $23.44 $226,244 - $314,541
-13,419 Reduced 28.06%
34,411 $796,000
Q2 2020

Aug 14, 2020
SELL
$16.86 - $23.44 $226,244 - $314,541
-13,419 Reduced 28.06%
34,411 $797,000
Q1 2020

Jul 12, 2023
BUY
$14.47 - $27.96 $547,327 - $1.06 Million
37,825 Added 378.06%
47,830 $853,000
Q1 2020

Mar 30, 2023
SELL
$14.47 - $27.96 $37,593 - $72,640
-2,598 Reduced 5.15%
47,830 $853,000
Q1 2020

May 15, 2020
SELL
$14.47 - $27.96 $37,593 - $72,640
-2,598 Reduced 5.15%
47,830 $854,000
Q4 2019

Jul 12, 2023
BUY
$15.87 - $23.12 $641,513 - $934,579
40,423 Added 404.03%
50,428 $1.09 Million
Q4 2019

Mar 30, 2023
BUY
$15.87 - $23.12 $361,629 - $526,835
22,787 Added 82.44%
50,428 $1.09 Million
Q4 2019

Feb 14, 2020
BUY
$15.87 - $23.12 $361,629 - $526,835
22,787 Added 82.44%
50,428 $1.09 Million
Q3 2019

Jul 12, 2023
BUY
$16.91 - $36.27 $298,224 - $639,657
17,636 Added 176.27%
27,641 $503,000
Q3 2019

Mar 30, 2023
SELL
$16.91 - $36.27 $100,901 - $216,423
-5,967 Reduced 17.75%
27,641 $503,000
Q3 2019

Nov 14, 2019
SELL
$16.91 - $36.27 $100,901 - $216,423
-5,967 Reduced 17.75%
27,641 $503,000
Q2 2019

Jul 12, 2023
BUY
$31.0 - $36.3 $731,693 - $856,788
23,603 Added 235.91%
33,608 $1.2 Million
Q2 2019

Mar 30, 2023
BUY
$31.0 - $36.3 $43,896 - $51,400
1,416 Added 4.4%
33,608 $1.2 Million
Q2 2019

Aug 14, 2019
BUY
$31.0 - $36.3 $43,896 - $51,400
1,416 Added 4.4%
33,608 $1.2 Million
Q1 2019

Jul 13, 2023
BUY
$31.58 - $46.35 $700,665 - $1.03 Million
22,187 Added 221.76%
32,192 $1.08 Million
Q1 2019

Mar 30, 2023
BUY
$31.58 - $46.35 $658,506 - $966,490
20,852 Added 183.88%
32,192 $1.08 Million
Q1 2019

May 16, 2019
SELL
$31.58 - $46.35 $168,700 - $247,601
-5,342 Reduced 14.23%
32,192 $1.08 Million
Q1 2019

May 15, 2019
BUY
$31.58 - $46.35 $146,025 - $214,322
4,624 Added 14.05%
37,534 $757,000
Q4 2018

Jul 13, 2023
BUY
$30.43 - $56.65 $696,999 - $1.3 Million
22,905 Added 228.94%
32,910 $1.08 Million
Q4 2018

Feb 14, 2019
BUY
$30.43 - $56.65 $12,202 - $22,716
401 Added 1.23%
32,910 $1.08 Million
Q3 2018

Jul 13, 2023
BUY
$46.46 - $68.49 $1.05 Million - $1.54 Million
22,504 Added 224.93%
32,509 $1.98 Billion
Q3 2018

Nov 14, 2018
BUY
$46.46 - $68.49 $28,991 - $42,737
624 Added 1.96%
32,509 $1.98 Million
Q2 2018

Aug 15, 2018
SELL
$46.25 - $104.45 $1.62 Million - $3.66 Million
-34,996 Reduced 52.33%
31,885 $0
Q1 2018

May 15, 2018
BUY
$57.4 - $108.44 $1.2 Million - $2.27 Million
20,923 Added 45.53%
66,881 $0
Q4 2017

Feb 15, 2018
SELL
$23.02 - $60.5 $1.23 Million - $3.24 Million
-53,608 Reduced 53.84%
45,958 $2.75 Million
Q2 2017

Aug 14, 2017
BUY
N/A
99,566
99,566 $1.95 Million

Others Institutions Holding NKTR

# of Institutions
140
Shares Held
135M
Call Options Held
32.8K
Put Options Held
55.5K
View Full List

About NEKTAR THERAPEUTICS

NKTR Quotes by TradingView
  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Metropolitan Life Insurance CO Portfolio

Follow Metropolitan Life Insurance CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

News

Stay updated on Metropolitan Life Insurance CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email